A Study Evaluating The Efficacy And Safety Of CP-690,550 In Asian Subjects With Moderate To Severe Plaque Psoriasis

Authors
Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2013
The primary objective of this study is to compare the efficacy of CP-690,550 (5 mg BID and 10 mg BID) versus placebo for the reduction in severity of plaque psoriasis after 16 weeks of treatment in Asian subjects with moderate to severe chronic plaque psoriasis who are candidates for systemic therapy or phototherapy.
Epistemonikos ID: bd6fd2a1b24ffbc94cb64f261eee19734961506c
First added on: May 11, 2024